Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

被引:11
|
作者
Machiraju, Devayani [1 ,2 ]
Schaefer, Sarah [3 ]
Hassel, Jessica C. [1 ,2 ]
机构
[1] Univ Hosp Heidelberg, Dept Dermatol, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Univ Heidelberg Hosp, Dept Dermatol, D-69120 Heidelberg, Germany
来源
LIFE-BASEL | 2021年 / 11卷 / 12期
关键词
age; melanoma; immunotherapy; tumor antigenicity; Tregs; gender; gut microbiome; stress; radiation; vaccination; IMMUNE CHECKPOINT INHIBITOR; CELL LUNG-CANCER; GUT MICROBIOTA; METASTATIC MELANOMA; DNA-DAMAGE; T-CELLS; COMBINATION THERAPY; CHOICE CHEMOTHERAPY; ANTITUMOR IMMUNITY; COMBINED NIVOLUMAB;
D O I
10.3390/life11121318
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
    Shui, Irene M.
    Scherrer, Emilie
    Frederickson, Andrew
    Li, Joyce W.
    Mynzhassarova, Anel
    Druyts, Eric
    Tawbi, Hussein
    MELANOMA RESEARCH, 2022, 32 (06) : 393 - 404
  • [2] Older Melanoma Patients May Respond Better to Anti-PD1 Immunotherapy
    不详
    CANCER, 2018, 124 (20) : 3961 - 3961
  • [4] Proteomic and Metabolomic Profiling of Female Patients with advanced Melanoma to Predict and Monitor Response to anti-PD1 Immunotherapy
    Paulitschke, V.
    Zila, N.
    Bileck, A.
    Stary, G.
    Borik-Heil, L.
    Dadak, L.
    Wolf, M.
    Wasinger, D.
    Aguilar-Gonzales, A.
    Harikumar, N.
    Kunstfeld, R.
    Weninger, W. P.
    Hoeller, C.
    Gerner, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 33 - 34
  • [5] Purple papules during anti-PD1 immunotherapy for metastatic melanoma
    De Luca, Erika V.
    Catapano, Silvia
    Del Regno, Laura
    Di Stefani, Alessandro
    Peris, Ketty
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (04): : 630 - 632
  • [6] VEDOLIZUMAB PLUS ANTI-PD1 ANTIBODY IN ADVANCED MELANOMA PATIENTS WITH INFLAMMATORY ENTEROCOLITIS
    Javed, Asad
    Freesmeier, Michele
    Zakharia, Yousef
    Milhem, Mohammed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1313 - A1313
  • [7] The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma
    Rose, April A. N.
    Armstrong, Susan M.
    Hogg, David
    Butler, Marcus
    Joshua, Anthony M.
    Ghazarian, Danny
    Kamel-Reid, Suzanne
    Al Habeeb, Ayman
    Chappell, Mary Anne
    Ross, Kendra
    Amir, Eitan
    Bedard, Phillippe L.
    Siu, Lillian
    Spreafico, Anna
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma
    Roncati, Luca
    ACTA DERMATOVENEROLOGICA CROATICA, 2018, 26 (04) : 341 - 343
  • [9] Auranofin and the efficacy of anti-PD1 immunotherapy
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma
    Fujimura, Taku
    Tanita, Kayo
    Ohuchi, Kentaro
    Sato, Yota
    Lyu, Chunbing
    Kambayashi, Yumi
    Fujisawa, Yasuhiro
    Tanaka, Ryota
    Hashimoto, Akira
    Aiba, Setsuya
    MELANOMA RESEARCH, 2020, 30 (06) : 613 - 618